Daniel B Soland - Net Worth and Insider Trading
Daniel B Soland Net Worth
The estimated net worth of Daniel B Soland is at least $299,500 dollars as of 2024-04-27. Daniel B Soland is the Director of ACADIA Pharmaceuticals Inc and owns about 10,000 shares of ACADIA Pharmaceuticals Inc (ACAD) stock worth over $167,100. Daniel B Soland is the Director of KalVista Pharmaceuticals Inc and owns about 10,000 shares of KalVista Pharmaceuticals Inc (KALV) stock worth over $107,800. Daniel B Soland is also the Director of DBV Technologies SA and owns about 20,000 shares of DBV Technologies SA (DBVT) stock worth over $13,640. Besides these, Daniel B Soland also holds Aceragen Inc (ACGN) . Details can be seen in Daniel B Soland's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Daniel B Soland has not made any transactions after 2023-08-01 and currently still holds the listed stock(s).
Transaction Summary of Daniel B Soland
Daniel B Soland Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Daniel B Soland owns 4 companies in total, including KalVista Pharmaceuticals Inc (KALV) , ACADIA Pharmaceuticals Inc (ACAD) , and Aceragen Inc (ACGN) among others .
Click here to see the complete history of Daniel B Soland’s form 4 insider trades.
Insider Ownership Summary of Daniel B Soland
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| KALV | KalVista Pharmaceuticals Inc | 2020-10-01 | director |
| ACAD | ACADIA Pharmaceuticals Inc | 2019-06-26 | director |
| ACGN | Aceragen Inc | 2021-03-05 | Chief Operating Officer |
| DBVT | DBV Technologies SA | 2023-08-01 | director |
Daniel B Soland Latest Holdings Summary
Daniel B Soland currently owns a total of 4 stocks. Among these stocks, Daniel B Soland owns 10,000 shares of ACADIA Pharmaceuticals Inc (ACAD) as of March 2, 2018, with a value of $167,100 and a weighting of 55.79%. Daniel B Soland owns 10,000 shares of KalVista Pharmaceuticals Inc (KALV) as of September 27, 2019, with a value of $107,800 and a weighting of 35.99%. Daniel B Soland also owns 20,000 shares of DBV Technologies SA (DBVT) as of August 1, 2023, with a value of $13,640 and a weighting of 4.55%. The other 1 stocks Aceragen Inc (ACGN) have a combined weighting of 3.66% among all his current holdings.
Latest Holdings of Daniel B Soland
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc | 2018-03-02 | 10,000 | 16.71 | 167,100 |
| KALV | KalVista Pharmaceuticals Inc | 2019-09-27 | 10,000 | 10.78 | 107,800 |
| DBVT | DBV Technologies SA | 2023-08-01 | 20,000 | 0.68 | 13,640 |
| ACGN | Aceragen Inc | 2021-03-05 | 28,843 | 0.38 | 10,960 |
Holding Weightings of Daniel B Soland
Daniel B Soland Form 4 Trading Tracker
According to the SEC Form 4 filings, Daniel B Soland has made a total of 0 transactions in ACADIA Pharmaceuticals Inc (ACAD) over the past 5 years. The most-recent trade in ACADIA Pharmaceuticals Inc is the acquisition of 10,000 shares on March 2, 2018, which cost Daniel B Soland around $234,900.
According to the SEC Form 4 filings, Daniel B Soland has made a total of 1 transactions in KalVista Pharmaceuticals Inc (KALV) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in KalVista Pharmaceuticals Inc is the acquisition of 10,000 shares on September 27, 2019, which cost Daniel B Soland around $118,700.
According to the SEC Form 4 filings, Daniel B Soland has made a total of 1 transactions in DBV Technologies SA (DBVT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in DBV Technologies SA is the acquisition of 15,000 shares on August 1, 2023, which cost Daniel B Soland around $24,300.
More details on Daniel B Soland's insider transactions can be found in the Insider Trading History of Daniel B Soland table.Insider Trading History of Daniel B Soland
- 1
Daniel B Soland Trading Performance
GuruFocus tracks the stock performance after each of Daniel B Soland's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Daniel B Soland is -22.38%. GuruFocus also compares Daniel B Soland's trading performance to market benchmark return within the same time period. The performance of stocks bought by Daniel B Soland within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Daniel B Soland's insider trading performs compared to the benchmark.
Performance of Daniel B Soland
Average Return
-23.08%
Outperforming Transactions
67%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -21.37 | -22.38 | -49.45 | -23.08 | -4.53 | 16.02 |
| Relative Return to S&P 500(%) | -22.07 | -25.8 | -54.17 | -32.48 | -15.27 | 6 |
Daniel B Soland Ownership Network
Ownership Network List of Daniel B Soland
Ownership Network Relation of Daniel B Soland
Daniel B Soland Owned Company Details
What does KalVista Pharmaceuticals Inc do?
Who are the key executives at KalVista Pharmaceuticals Inc?
Daniel B Soland is the director of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include Chief Scientific Officer Edward P. Feener , Chief Medical Officer Paul K. Audhya , and CFO and Secretary Benjamin L Palleiko .
KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary
Over the past 18 months, Daniel B Soland made no insider transaction in KalVista Pharmaceuticals Inc (KALV). Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net purchase of 1,251,017 shares made by Venrock Healthcare Capital Partners Iii, L.p. , a net sale of 167,039 shares made by Thomas Andrew Crockett , and a net sale of 110,937 shares made by Edward P. Feener .
In summary, during the past 3 months, insiders sold 279,594 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 265,951 shares, with a net sale of 13,643 shares. During the past 18 months, 505,299 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 1,251,017 shares were bought by its insiders, resulting in a net purchase of 745,718 shares.
KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.
KalVista Pharmaceuticals Inc Insider Transactions
Daniel B Soland Mailing Address
Above is the net worth, insider trading, and ownership report for Daniel B Soland. You might contact Daniel B Soland via mailing address: 4560 Horton Street,m/s R-422, Emeryville Ca 94608.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
